Personality Pharmacology

Part V · Pharmacology of the Self Draft

Chapter 30

The One-Third Problem and Precision Psychopharmacology

Psychopharmacology is full of averages that no individual patient experiences.

A trial concludes that a treatment reduces symptoms by a certain number of points. The clinician sees a different distribution: one patient transforms, one improves modestly, one feels nothing, one stops because of adverse effects, and one becomes worse.

The exact proportions vary enormously. The “one-third problem” is therefore not a statistical law. It is a heuristic: in many clinical situations, substantial response, partial response, and poor response coexist within the same diagnostic group.

That heterogeneity is not a minor inconvenience. It may be the central scientific problem.

Consider major depression. The diagnosis can contain profound anhedonia, anxiety, insomnia, hypersomnia, psychomotor slowing, agitation, guilt, cognitive impairment, appetite change, social withdrawal, and suicidal thinking in different combinations. Two patients can meet criteria with little symptom overlap.

Below the symptom level, heterogeneity expands further. One person may have severe reward-system dysfunction. Another may be chronically hyperaroused. Another may have bipolar-spectrum instability. Another may be responding to trauma. Another may have endocrine disease, chronic inflammation, circadian disruption, a toxic social environment, or several interacting factors.

The same label can represent different starting systems.

Interactive figure: The one-third problem.

Figure 30.1The one-third problem. Give everyone with the same diagnosis the same drug and outcomes scatter. Choosing per person helps exactly as much as the starting point can be measured. Illustrative model, not measured data.

Yet the conventional treatment question is still often phrased as “Which drug treats depression?”

Personality pharmacology proposes a different question: “Which control process is producing this person's impairment, where is the person starting, and which perturbation is most likely to move them toward a functional region?”

This is precision psychopharmacology in its strong form.

The idea is not new in spirit. Medicine routinely conditions treatment on biomarkers, disease subtype, renal function, genetics, age, and prior response. Psychiatry already uses some obvious stratification, such as distinguishing bipolar from unipolar depression or avoiding particular drugs after previous adverse reactions.

The claim is that much more predictive information may be hiding in dimensional phenotype.

Potential inputs include reward sensitivity, harm avoidance, impulsivity, arousal, sleep and circadian patterns, personality facets, cognitive tasks, prior medication response, family history, pharmacogenomics, endocrine state, inflammatory markers, neuroimaging, substance sensitivity, and longitudinal variation.

The key phrase is potential inputs. Precision medicine has a long history of measuring impressive things that fail to improve decisions.

A biomarker is valuable only if it changes expected outcome enough to alter what we do.

This gives the field a clear standard. A complex personalization model should be compared prospectively with a simpler treatment policy. Does conditioning treatment on the model improve remission, function, tolerability, or time to effective therapy? If not, the model has explained variance without earning clinical authority.

Personality measures are especially interesting because they are cheap and longitudinally meaningful. If a stable trait such as reward sensitivity or harm avoidance predicts response to a pharmacological class, that would be clinically useful even if the trait is only an indirect proxy for mechanism.

One research design suggested by this framework is to measure personality after acute illness has remitted and ask whether the resulting profile predicts or retrospectively distinguishes responses to drugs with different dominant mechanisms. The post-remission timing attempts to reduce contamination by the episode itself.

Retrospective studies would be only a beginning. The stronger design is prospective. Measure baseline dimensions before treatment. Randomize or otherwise compare plausible interventions. Test a preregistered interaction between phenotype and treatment. Replicate it in a new sample.

Measure baseline dimensionsbefore any treatmentCompare plausible treatmentsrandomised where possibleTest a preregistered interactionphenotype × treatmentReplicatein a new sample
Figure 30.2The stronger design. Measure first, treat second, and test a prediction made in advance.

The target is not a post hoc story about why responders responded.

Longitudinal within-person data may prove even more valuable. One individual’s response to sleep deprivation, stress, stimulants, serotonergic drugs, exercise, or menstrual or seasonal changes can reveal structure that a single baseline visit misses. A person is not only a point in population space; they are a time series.

This is where modern sensing becomes useful, but only if it serves a theory. Sleep timing, activity, heart rate, ecological mood, work patterns, and social behavior can produce enormous datasets. Without clear hypotheses they become digital noise. With a model, they can estimate state and transitions.

The “one-third problem” also has an ethical consequence. When treatments are prescribed on average evidence, nonresponders can be interpreted as difficult patients or treatment resistant. A baseline-interaction model shifts some responsibility back to the treatment policy. The drug may not have failed because the patient is refractory. The intervention may simply have been poorly matched.

That does not mean every poor response was predictable. Biology can remain stochastic and measurements imperfect. Precision psychiatry should not promise individualized certainty.

Its rational goal is smaller: improve the odds.

Even modest predictive gains matter when treatments take weeks, adverse effects are substantial, or untreated illness is dangerous.

The framework also challenges diagnosis as the final unit of pharmacology. Diagnoses may remain essential for communication while becoming only one layer of the treatment model. A future clinician might use a diagnosis to identify a broad syndrome and a dimensional profile to choose among interventions within it.

The transition resembles oncology’s movement from organ labels toward molecular subtypes, but the analogy should not be stretched. Psychiatric mechanisms are likely to be more distributed, state-dependent, and context-sensitive than many tumor markers.

Still, the direction is clear.

The ultimate promise of personality pharmacology is not that personality replaces diagnosis. It is that stable and dynamic features of the person become explicit variables in treatment selection.

Once that happens, another boundary becomes difficult to defend. If we can deliberately target a dimension because it causes illness, why must the same dimension become untouchable the moment the person crosses into the statistically normal range?